Downregulation of zinc finger protein 71 in laryngeal squamous cell carcinoma tissues and its potential molecular mechanism and clinical significance: a study based on immunohistochemistry staining and data mining

Fang-Cheng Jiang1, Jia-Yuan Luo1, Yi-Wu Dang1, Hui-Ping Lu1, Dong-Ming Li1, Zhi-Guang Huang1, Yu-Lu Tang1, Ye-Ying Fang2, Yu-Xing Tang2, Ya-Si Su3, Wen-Bin Dai3, Shang-Ling Pan4, Zhen-Bo Feng1, Gang Chen1 and Juan He1*

Abstract

Background: The molecular mechanism of laryngeal squamous cell carcinoma (LSCC) is not completely clear, which leads to poor prognosis and treatment difficulties for LSCC patients. To date, no study has reported the exact expression level of zinc finger protein 71 (ZNF71) and its molecular mechanism in LSCC.

Methods: In-house immunohistochemistry (IHC) staining (33 LSCC samples and 29 non-LSCC samples) was utilized in analyzing the protein expression level of ZNF71 in LSCC. Gene chips and high-throughput sequencing data collected from multiple public resources (313 LSCC samples and 192 non-LSCC samples) were utilized in analyzing the exact mRNA expression level of ZNF71 in LSCC. Single-cell RNA sequencing (scRNA-seq) data was used to explore the expression status of ZNF71 in different LSCC subpopulations. Enrichment analysis of ZNF71, its positively and differentially co-expressed genes (PDCEGs), and its downstream target genes was employed to detect the potential molecular mechanism of ZNF71 in LSCC. Moreover, we conducted correlation analysis between ZNF71 expression and immune infiltration.

Results: ZNF71 was downregulated at the protein level (area under the curve [AUC] = 0.93, p < 0.0001) and the mRNA level (AUC = 0.71, p = 0.023) in LSCC tissues. Patients with nodal metastasis had lower protein expression level of ZNF71 than patients without nodal metastasis (p < 0.05), and male LSCC patients had lower mRNA expression level of ZNF71 than female LSCC patients (p < 0.01). ZNF71 was absent in different LSCC subpopulations, including cancer cells, plasma cells, and tumor-infiltrated immune cells, based on scRNA-seq analysis. Enrichment analysis showed that ZNF71 and its PDCEGs may influence the progression of LSCC by regulating downstream target genes of ZNF71.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant tumors in the head and neck, with a high metastatic rate and recurrence rate [1]. At present, treatment methods include surgery, radiotherapy, and chemotherapy [2, 3]. Despite therapeutic progress, overall mortality remains approximately 50%, and the quality of life of patients is poor, especially for advanced patients [1, 4]. To date, there is no tool to predict the evolution of this type of cancer [5]. The molecular mechanism of LSCC also remains unclear. Therefore, many studies have been conducted to find biological indicators related to the invasion and metastasis of LSCC in recent years to provide a new direction for clinical treatment by elucidating the molecular mechanism.

Zinc finger protein (ZNF), the largest transcription factor (TF) family in the human genome, has an extraordinarily diverse set of functions, including DNA recognition, transcriptional activation, RNA packaging, apoptosis regulation, protein folding and assembly, and lipid binding [6]. In a recent study by Jen and Wang shows, ZNF influences cancer progression by abnormally expressing proteins [6]. As a member of the family, ZNF71 expression is associated with chemical sensitivity, and protein expression correlates with the prognosis of non-small cell lung cancer (NSCLC) [7]. Increased ZNF71 protein expression is positively related to a favorable prognosis in NSCLC [8]. Moreover, the expression of ZNF71 was lower in the high-risk group than in the low-risk group of osteosarcoma patients with poor prognoses [9]. However, to the authors’ knowledge, no study has proven the specific expression status and potential molecular mechanism of ZNF71 in LSCC.

Therefore, the present study aims to determine the specific expression level of ZNF71 in LSCC by analyzing a large of samples from multi-centers and in-house immunohistochemistry (IHC) staining results. In this study, single-cell RNA sequencing (scRNA-seq) results revealed the expression status in different subpopulations of patients with LSCC. Then, the potential molecular mechanism of ZNF71 in LSCC was explored by conducting enrichment analysis and predicting the immune-infiltration landscape.

Materials and methods
Evaluation of ZNF71 protein expression in LSCC tissues based on in-house immunohistochemistry staining
We purchased 33 LSCC tissue microarray samples (number HNT1021) and 17 normal laryngeal tissue microarray samples (number HNT1021) from Guilin Fanpu Biotech (Guangxi, China), and these samples were collected from the north of Guangxi. We also collected 12 non-cancerous squamous epitheliums of laryngeal tissues from the First Affiliated Hospital of Guangxi Medical University, China. These samples were collected from the south of Guangxi which includes 6 benign papilloma of laryngeal tissue samples and 6 normal laryngeal tissue samples. Our work was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (number 2021-KY-E-117). All study participants agreed to the study, and we received written informed consent from study participants. In total, we collected 33 LSCC samples and 29 non-LSCC tissue samples. Furthermore, we downloaded subcellular location images from the Human Protein Atlas (HPA) website (https://www.proteinatlas.org/ENSG00000197951-ZNF71/subcellular) to identify the subcellular location of the ZNF71 protein.

ZNF71 polyclonal antibody was purchased from biorbyt, and it is a rabbit-anti-human antibody (No. orb335284). We used the antibody for IHC staining (dilution 1:100) and operated strictly under the manufacturer’s instructions. The tissue slides had been formalin-fixed and paraffin-embedded, so we deparaffinized and rehydrated them. Then, we incubated them with 3% H2O2 for 5–10 min, rinsed them with distilled water, and soaked them in phosphate-buffered saline (PBS). We blocked the slides with the purchased ZNF71 antibody and washed them with PBS. Then, the tissue slides were re-stained, dehydrated, made transparency, and sealed. We performed these procedures at room temperature. Finally, two pathologists scored the final IHC tissue slides according to the staining intensity and quantity of positive cells (proportion of stained cells in tumor cells of the whole visual field). The scores of staining intensity followed the criteria: no staining/blue (point 0), weak staining/light yellow (point 1), moderate staining/tan (point 2), and strong staining/sepia (point 3). The scoring criteria was as follows: 0–5% (point 0), 6–25% (point 1),
25–50% (point 2), 50–75% (point 3), and 75–100% (point 4). The final score for each slide was the average of the total IHC scores determined by each of the two pathologists. More specific information can be referenced in previous work by our team [10–12]. And the raw data for IHC staining is presented in Table S1.

We statistically analyzed and visualized the expression differences of ZNF71 in LSCC samples and non-LSCC samples through GraphPad Prism v8.2.1 software. T test was used here, and p value < 0.05 was considered that the results have statistical significance. And we plotted the receiver operating characteristic (ROC) curve and calculated the area under the curve (AUC) value through GraphPad Prism v8.2.1 software.

Identification of ZNF71 mRNA expression in LSCC tissues based on data collected from multi-centers

We collected extensive LSCC and non-cancerous laryngeal tissue samples from several public databases, such as Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), Sequence Read Archive (SRA), ArrayExpress, and Oncomine. The search terms, inclusion criteria, and exclusion criteria can be referenced in previous work by our team [11]. Finally, 12 datasets across 10 platforms were obtained. The specific information is presented in Table S2. We then removed the batch effect of datasets from the same platform and combined them via the sva package (https://bioconductor.org/packages/sva/) in RStudio v3.6.1. We considered the expression values of ZNF71 which were not normalized by the sva package (https://bioconductor.org/packages/meta/index.html) in RStudio v3.6.1. We logarithmically processed the expression value of ZNF71 in each cell subpopulations and the data is presented in Table S3. We then calculated the standardized mean difference (SMD) value in the Stata v12.0 software using the expression values of ZNF71 gene. The fixed-effect model was used because I² < 50%. |SMD| > 0 and p value < 0.05 were considered that the results have statistical significance. Through the Stata v12.0 software, we conducted sensitivity analysis to assess the stability of the results. Then, we used Begg’s and Egger’s test to test the publication bias of included cohorts. Here, p value > 0.05 was considered the included datasets have no publication bias. We also plotted the ROC curve and calculated the AUC value of the ROC curve via GraphPad Prism v8.2.1 software. We next plotted the summary ROC (sROC) curve using the expression values of ZNF71 and calculated the AUC of the sROC curve with Stata v12.0 software. Deek’s test was used to test the publication bias, and p value > 0.05 indicated no publication bias. We created a forest plot to describe the variance of sensitivity and specificity using the Stata v12.0 software. We also performed correlation analysis between ZNF71 expression and clinic-pathological parameters using TCGA_LSCC clinical data through GraphPad Prism v8.2.1 software.

Detection of ZNF71 expression landscape based on single-cell RNA sequencing analysis

To explore the expression status in LSCC across different subpopulations, we collected a scRNA-seq dataset (GSE150321) and selected one untreated LSCC sample from the dataset named GSM4546858 for analysis [13]. We used a seurat process for scRNA-seq dataset analysis via the Seurat (https://cloud.r-project.org/package=Seurat) package in RStudio v3.6.1 [14]. We set filtering conditions for quality control, and after screening, all cells we remained these cells with numbers of genes exceeding 50 and numbers of mitochondrial genes less than 30%. We then standardized the total gene expression value of the remaining cells via the Seurat package in RStudio v3.6.1. And we scaled the data and analyzed the principal components. After dimensionality reduction using the Seurat package, we selected the first 20 principal components for subsequent analysis. Here, we used the t-distributed stochastic neighbor embedding (tSNE) method for dimension reduction and clustering. We used “FindClusters” function to divide LSCC cells with resolution = 0.5. Finally, we identified 15 clusters via the Seurat package in RStudio v3.6.1. We showed the logarithmically processed expression value of ZNF71 in each cell subpopulations and visualized it via the Seurat package in RStudio v3.6.1. We then annotated the cell type of each cluster according to the method provided by dataset contributors [13]. And we visualized it in RStudio v3.6.1.

Enrichment analysis for PDCEGs and downstream target genes of ZNF71

Pearson correlation analysis was used to calculate the positive co-expressed genes of ZNF71 from 10 cohorts via the Pearson function in RStudio v3.6.1. The screening conditions were as follows: (a) p value < 0.01, (b) r (Pearson correlation coefficient) ≥ 0.4, and (c) repetition ≥ 2. After intersecting with the downregulated gene set, a total of 106 positively and differentially co-expressed genes (PDCEGs) was obtained and these PDCEGs are presented in Table S4. We calculated the SMD values for each gene to identify differentially expressed genes (DEGs) from 10 cohorts via the meta package (http://cran.r-project.org/web/packages/meta/index.html) in RStudio v3.6.1. We considered DEGs with criteria value of |SMD| > 0 and of p value < 0.05. Results are expected to be more reliable due to the multiple datasets included. Then, we constructed a protein–protein interaction network (PPI) to explore the relationships
between those PDCEGs and annotated their biological function and signaling pathways through the STRING website (https://string-db.org/) [15]. We used the Cistrome Data Browser (DB) (http://cistrome.org/db), an online tool derived from chromatin immunoprecipitation and DNA sequencing (ChIP-seq) chromatin profiling assays, assay for transposase-accessible chromatin with high throughput sequencing (ATAC-seq), and DNA affinity purification sequencing (DNase-seq), to predict the downstream target genes of ZNF71 [16]. We set filtering conditions, namely a score greater than 0.1 and positive strand. After intersecting with the downregulated genes in LSCC, a total of 889 target genes was obtained. Then, we used Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis to annotate the function and signaling pathway of these target genes via the ClusterProfiler package (https://bioconductor.org/packages/clusterProfiler/) in RStudio v3.6.1.

**Correlation analysis between ZNF71 expression and immune infiltration in LSCC**

The ESTIMATE algorithm is a method for inferring the fraction of stromal and immune cells in tumor samples using gene expression signatures [17]. We calculated the ESTIMATE score of each TCGA_LSCC sample via the ESTIMATE package (https://r-forge.r-project.org/projects/estimate/) in RStudio v3.6.1. Then, we performed correlation analysis between the ESTIMATE score and ZNF71 expression in GraphPad Prism v8.2.1 software. To further explore the relationship between ZNF71 expression and tumor-infiltration lymphocytes (TILs), we used TISIDB to analyze it. TISIDB (http://cis.hku.hk/TISIDB) is a user-friendly web portal that pre-calculates the associations between any gene and immune features [18]. Then we calculated the association between ZNF71 expression and immune infiltration for the TCGA_LSCC samples.

**Statistical analysis**

In this study, the software GraphPad Prism v8.2.1, Stata v.12.0, RStudio v3.6.1 were used for statistical analysis and results visualization. In GraphPad Prism v8.2.1 software, the t test was used for data that met both normal distribution and variance homogeneity parameters; the Wilcoxon test was used for other data. We used the interval estimation method to calculate the 95% confidence interval (95% CI). And p value < 0.05 was considered the results have statistical significance.

**Results**

**ZNF71 was downregulated at the protein level in LSCC tissues**

According to the results from the HPA website, the ZNF71 protein is mainly localized to the nucleoli (Figure S1). In the IHC staining of non-cancerous laryngeal tissues, we observed that the staining of the nucleus was positive (Fig. 1A, B), while in the IHC staining of LSCC tissues, the staining of whole tissues was negative (Fig. 1C, D). To further quantify the results, we calculated the statistical difference between the IHC scores of the LSCC and non-LSCC tissues, and the results showed that the expression of ZNF71 was downregulated in LSCC tissues (p < 0.0001, Fig. 1E). And the ROC curve indicated that the ZNF71 protein has great discriminatory ability between LSCC and non-LSCC tissues (p < 0.0001, Fig. 1F). Moreover, the correlation analysis between the protein expression of ZNF71 and clinicopathologic parameters were conducted. The results showed us that patients with different T stage had no difference of ZNF71 expression (p > 0.05, Fig. 1G). However, patients with nodal metastasis had lower protein expression level of ZNF71 than patients without nodal metastasis (p < 0.05, Fig. 1H).

**ZNF71 was downregulated at the mRNA level in LSCC based on comprehensive analysis**

We comprehensively analyzed the multiple datasets to clarify the exact expression status of ZNF71 in LSCC. The forest plot showed that ZNF71 was downregulated at mRNA level in LSCC (total SMD: −0.22, 95% CI, −0.42−−0.03, Fig. 2A). Sensitivity analysis (Fig. 2B) showed that the results from the included datasets were robust. We tested the publication bias, and the Begg’s test (p = 0.283, Fig. 2C) and Egger’s test (p = 0.438, Fig. 2D) showed that there was no publication bias. After comprehensive analysis, it was confirmed that the expression of ZNF71 was downregulated in LSCC tissues. Furthermore, we integrated the mRNA data and the protein data of in-house IHC, and we found the downregulation status of ZNF71 in LSCC tissues (total SMD: −0.40, 95% CI, −0.58−−0.21, Fig. 2E).

To explore the discriminatory ability of ZNF71 expression between LSCC and non-cancerous laryngeal tissues, we analyzed the ROC curves of all included datasets and calculated the AUC values (Fig. 3A). We further analyzed the sROC curve to describe this discriminatory ability more intuitively. The results of the sROC showed that ZNF71 has moderate discriminatory ability in LSCC (AUC [See figure on next page.]

**Fig. 1**  IHC staining of ZNF71 protein in laryngeal squamous cell carcinoma (LSCC) and non-LSCC tissues. **A, B** Expression level of ZNF71 protein in normal laryngeal tissues (left: x200; right: x400). **C, D** Expression level of ZNF71 protein in LSCC tissues (left: x200; right: x400). **E** Scatter plot of IHC score. **F** The ROC curve of ZNF71 expression. **G, H** Differentially expression analysis of ZNF71 protein between different T stage (G) and N stage (H). Note: ns: non-significant; *p < 0.05; **p < 0.01
Fig. 1 (See legend on previous page.)
Deek's test showed that the included datasets had no publication bias ($p = 0.969$, Fig. 3C). The total sensitivity of the included datasets was 0.50 (95% CI, 0.39–0.60, Fig. 3D), and the total specificity was 0.89 (95% CI, 0.78–0.95, Fig. 3E).

We also analyzed the relationship between the expression of ZNF71 and clinicopathological parameters of LSCC patients. Male LSCC patients had lower mRNA expression level of ZNF71 than female LSCC patients ($p = 0.0046$, Fig. 4A). But there was no expression difference in non-cancerous samples across genders ($p > 0.05$, Figure S2). Among other clinicopathological parameters, there was no significant difference in the expression of ZNF71 ($p > 0.05$, Figure S2). And ZNF71 expression was not related to survival time ($p > 0.05$, Fig. 4H).

ZNF71 was absent in LSCC in different subpopulations based on scRNA-seq analysis

In addition to the protein level and mRNA level, we further explored the expression of ZNF71 in LSCC at the cell level using scRNA-seq data. Firstly, after analyzing the scRNA-seq data and setting appropriate parameters, we divided the cells of LSCC into 15 cell clusters (Fig. 5A). Then, we analyzed and visualized the expression of ZNF71 in these cell clusters with the gene mapping map (Fig. 5B) and violin plot (Fig. 5C). The results showed that there was no expression of ZNF71 in various LSCC cells. Finally, we annotated the cell types according to the marker genes of these cell clusters and found that these cell types are cancer cells, plasma cells, macrophages, M2-macrophages, B cells, T cells, naive T cells, fibroblasts, epithelial cells, endothelial cells, and unidentified cell types (Fig. 5D).
To explore the potential molecular mechanism of ZNF71, we constructed a PPI network of ZNF71 and its PDCEGs and conducted enrichment analysis through the STRING website. The interactive relationship is presented in Fig. 6A. These PDCEGs of ZNF71 were mainly enriched in biological regulation, regulation of biological progress, and regulation of cellular progress in the biological process (BP). In cellular components (CC), they concentrated on the nucleus. In terms of molecular function (MF), they were mainly enriched in binding, iron binding, and organic cyclic compound binding. On the Reactome pathway, they were enriched in gene expression and the generic transcription pathway (Fig. 6B).

As ZNF71 is a transcription factor, we further predicted the downstream target genes of ZNF71 through Cistrome DB. We conducted enrichment analysis of ZNF71 and its target genes to explore the potential molecular mechanism of ZNF71 in LSCC.
Fig. 4 Clinical significance analysis of ZNF71 expression and gender (A), T_clinic (B), N_clinic (C), M_clinic (D), stage_clinic (E), stage_pathologic (F), N_pathologic (G), and survival time (H).
The correlation between the expression of ZNF71 and tumor immune infiltration

We further evaluated the relationship between ZNF71 expression and immune cells and stromal cells in the tumor immune microenvironment (TME) through the ESTIMATE algorithm. The expression of ZNF71 was positively correlated with immune cell score (Pearson $r = 0.2433$, $p = 0.0101$, Fig. 7B), but not with stromal cell score (Pearson $r = 0.1198$, $p = 0.2103$, Fig. 7C). Furthermore, based on the TISIDB online tool, we further analyzed the relationship between ZNF71 expression and 28 kinds of tumor-infiltrating lymphocytes. The results showed that the expression of ZNF71 was positively correlated with tumor-infiltrating lymphocytes, such as neutrophils, activated dendritic cells, type 17 helper cells, and monocytes (Fig. 7D).

Discussion

In the present study, we demonstrated that ZNF71 was downregulated in LSCC across in-house IHC staining (LSCC tissue samples = 33; non-cancerous laryngeal tissue samples = 29) and multiple datasets, including gene chips and high-throughput sequencing data (LSCC tissue samples = 313; non-cancerous laryngeal tissue samples = 192) from multi-centers. We found patients with nodal metastasis had lower protein expression level of ZNF71 than patients without nodal metastasis. Then,
we observed that the expression of ZNF71 was lower in male LSCC patients than female LSCC patients. Interestingly, according to cancer statistics in 2019, the incidence of laryngeal cancer in male patients was higher than in female patients [19]. Gender is an independent prognostic factor for LSCC patients [20]. Therefore, we speculated that downregulation of ZNF71 is related to the different incidence and pathogenesis of LSCC across genders. Moreover, we found no ZNF71 expression in LSCC samples from different subpopulations through scRNA-seq data analysis. We speculated that the absence

![Fig. 6 Potential molecular mechanism analysis of ZNF71 in LSCC. A) Protein-protein interactive network of ZNF71 and its positively and differentially co-expressed genes (PDCEGs). B) Enrichment analysis of ZNF71 and its PDCEGs. C-F Biological process (BP), cellular component (CC), molecular function (MF), and KEGG pathway signaling analysis for downstream target genes of ZNF71.](image-url)
of ZNF71 expression in LSCC is related to the pathogenesis of LSCC.

In order to explore the potential molecular mechanism of ZNF71 in LSCC, we conducted enrichment analysis of ZNF71 and its PDCEGs. The results suggest that ZNF71 may interact with its PDCEGs, affecting the transcription process of target genes, and thus may play a role in the occurrence and development of LSCC. Focusing on the function and pathways of ZNF71’s target genes, enrichment analysis showed that ZNF71 may promote the transcription process of membrane proteins and affect the tight junctions between cells. Tight junction proteins have been proven to be involved in epithelial-to-mesenchymal transition and to play an important role in the pathogenesis of some cancers [21, 22]. We found the significant downregulation of these tight junction-related genes in LSCC tissues. Therefore, we speculated that the absence of ZNF71 may promote LSCC development by reducing the tight junctions between tumor cells.

Interestingly, our results showed that patients with nodal metastasis had lower protein expression level of ZNF71 than patients without nodal metastasis. We then inferred that reduction of tight junctions associates with nodal metastasis.

Furthermore, we explored the relationship between ZNF71 expression and immune infiltration. According to the results, the expression of ZNF71 was positively correlated with immune cell score, but not with stromal cell score. Hence, we propose that the low expression of ZNF71 means a decrease in immune infiltration, but it does not affect stromal cells. We further calculated which immune cell was positively correlated with the expression of ZNF71. Among those correlative immune cells, neutrophil was most correlated with ZNF71 expression. In TME, neutrophils exert diverse functions [23, 24]. On the one hand, they have been described as a cancer-promoting factor and have been correlated with poor prognosis [23, 24]. Recent studies have revealed that

Fig. 7 Correlation analysis between ZNF71 expression and ESTIMATE score (A), immune score (B), stromal score (C), and tumor infiltration lymphocytes (TILs, D)
neutrophil extracellular traps released by activated neutrophils mediate the progression of tumors and awaken dormant tumor cells [25–27]. On the other hand, they can kill tumor cells as well. Neutrophils can affect tumor growth by orchestrating other immune cells in TME [23]. Overall, neutrophils play complex roles in tumors. Therefore, we speculated that ZNF71 may play a complex role in LSCC by influencing neutrophils. Moreover, it is also important to pay attention to the role of neutrophils in treatment. Previous evidence has shown that neutrophils mediate anti-tumor resistance [24, 28]. In this respect, we assumed that low immune infiltration of neutrophils is not always harmful. Hence, we propose that low expression of ZNF71 does not indicate poor outcome. Interestingly, this is consistent with the results of survival analysis.

Dendritic cells, as professional antigen presenting cells, are key regulators of the immune response within cancers [29, 30]. Moreover, dendritic cells are essential to the activation of effector memory T cells [31]. Interestingly, we observed a positive correlation between ZNF71 expression and these two immune cells. That means LSCC with low expression of ZNF71 has low infiltration of these two immune cells. However, effector memory T cells are crucial in the immune response against tumors [32]. We speculated that the absence of ZNF71 may influence the progression of LSCC by reducing these immune cells. Furthermore, we also found a positive correlation between ZNF71 expression and monocytes. Accumulating evidence has shown that monocytes contribute both to promoting the development of tumors and killing cancers [33, 34]. However, more evidence is needed regarding the function of the low infiltration of monocytes in tumors. Overall, in our results, the low expression of ZNF71 means that the infiltration of most TILs is reduced. TME with low immune infiltration will not only promote the progression of cancer, but also increase the difficulty of therapy [31]. Recent studies by Yan et al. also revealed that immune infiltration is correlated with TNM stages of patients with LSCC [35]. Interestingly, our work revealed that patients with nodal metastasis had lower expression level of ZNF71 than patients without nodal metastasis. Therefore, we speculated that downregulation of ZNF71 is related to immune infiltration and N stage. Taken together, we speculated that the downregulation of ZNF71 may influence the development of LSCC by reducing immune infiltration.

In summary, we demonstrated the downregulation of ZNF71 in LSCC, including different subpopulations of LSCC through data from multi-centers, IHC staining, and scRNA-seq data. We also explored the potential mechanism of ZNF71 in LSCC. The absence of ZNF71 may promote LSCC progression by reducing the tight junction between tumor cells and reducing immune infiltration. However, this study had some limitations. First, analysis between clinicopathologic parameters and the mRNA expression of ZNF71 was limited in TCGA data. Also, the in-house IHC sample size was small. Finally, the exact molecular mechanism of ZNF71 in LSCC requires further experiments in vivo and in vitro.

Conclusions

Downregulation of ZNF71 was demonstrated by in-house IHC staining and data collected from multi-centers. Also, downregulation of ZNF71 may be related to the different incidence and pathogenesis of LSCC across genders and may also associate with nodal metastasis. Single-cell RNA sequencing analysis also showed the absence of ZNF71 expression in LSCC in different subpopulations. Downregulation of ZNF71 may promote LSCC development by reducing the tight junction between tumor cells and reducing immune infiltration.

Abbreviations
LSCC: Laryngeal squamous cell carcinoma; ZNF: Zinc finger protein; TF: Transcription factor; NSCLC: Non-small cell lung cancer; IHC: Immunohistochemistry; ScRNA-seq: Single-cell RNA sequencing; HPA: The Human Protein Atlas; PBS: Phosphate-buffered saline; ROC: Receiver operating characteristic; AUC: Area under the curve; GEO: Gene Expression Omnibus; TCGA: The Cancer Genome Atlas; SRA: Sequence read archive; SMD: Standardized mean difference; sROC: Summary receiver operating characteristic; PDCEGs: Positively and differentially co-expressed genes; DEGs: Differentially expressed genes; PPI: Protein–protein interaction network; DB: Data browser; ChIP-seq: Chromatin immunoprecipitation and DNA sequencing chromatin profiling assays; ATAC-seq: Assay for transposase-accessible chromatin with high throughput sequencing; DNase-seq: DNA affinity purification sequencing; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; 95% CI: 95% confidence interval; BP: Biological process; CC: Cellular components; MF: Molecular function.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12957-022-02823-8.

**Additional file 1**: Table S1. Raw data for IHC staining.

**Additional file 2**: Table S2. Specific information of included datasets collected from public resources.

**Additional file 3**: Table S3. Expression values of ZNF71 extracted from included datasets.

**Additional file 4**: Table S4. Gene list of positively and differentially co-expressed genes of ZNF71.

**Additional file 5**: Table S5. Pearson correlation analysis between ZNF71 and its putative target genes which relates to tight junction.

**Additional file 6**: Figure S1. Subcellular location of ZNF71 protein (downloaded from HPA website).

**Additional file 7**: Figure S2. Expression difference of ZNF71 across genders.

**Additional file 8**: Figure S3. Expression analysis of ZNF71’s putative target and tight junctions-related genes.
Acknowledgements

We sincerely thank the patients who agreed to provide their data for scientific research, and this work was approved by them and the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University. We would like to thank these public resources for promoting the progress of human science. Gene Expression Omnibus (GEO), and The Cancer Genome Atlas (TCGA), Sequence Read Archive (SRA), ArrayExpress, and Oncomine database. And we sincerely thank those contributors who uploaded their data which were accessible. We also thank the developers of these tools. Human protein atlas (HPA) website, Cistrome database, STRING website, TISIDB, RStudio, sva package, ClusterProfiler package, ESTIMATE package, Seurat package, meta package, Sta software, and GraphPad Prism. We thank for the technical supports including computational pathology and experimental pathology provided by Guangxi Key Laboratory of Medical Pathology. And we are grateful to Guangxi Medical University and other institutions mentioned below for funding our work. Finally, we want to express our deep gratitude to editors and reviewers for reviewing our work.

Author statement

The work described has not been published previously, that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

Authors’ contributions

Fang-Cheng Jiang: data curation, formal analysis, investigation, writing—original draft, and visualization. Jia-Yuan Luo: data curation and funding acquisition. Hui-Ping Lu and Dong-Ming Li: data curation. Zhi-Guang Huang and Yi-Wu Dang: resources and methodology. Gang Chen: funding acquisition, resources, and methodology, writing—and reviewing and editing. Yu-Lu Tang, Ye-Ying Fang, and Yu-Xing Tang: funding acquisition and writing—original draft. Si-Yu Su and Wen-Bin Dai: methodology and writing—review and editing. Shang-Ling Pan and Zhen-Bin Feng: methodology, resources, supervision, and validation. Juan He: methodology, project administration, supervision, and validation. The authors read and approved the final manuscript.

Funding

This study was supported by the Future Academic Star of Guangxi Medical University (WLX52XG1118), Guangxi Medical University Undergraduate Innovation and Entrepreneurship Training Program (20210598040), Guangxi Higher Education Undergraduate Teaching Reform Project (2022), Guangxi Educational Science Planning Key Project (2021B167), and Guangxi Medical University Teacher Teaching Ability Development Project (2202JFA02).

Availability of data and materials

The following information was supplied regarding data availability: Datasets are available at NCBI GEO and TCGA databases: GSE12716S, GSE142083, GSE8991, GSE107591, GSE117005, GSE137308, GSE143224, GSE299330, GSE51985, GSE59102, GSE84957, GSE150321, and TCGA_LSCC data. And the date of immunohistochemistry staining used and/or analyzed during the current study is available at the supplemental materials.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University (number 2021-KY-E-117). All study participants agreed to the study, and we received written informed consent from study participants.

Consent for publication

The patients provided written informed consent for the publication of the data and any associated images.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, Guangxi Zhaung Autonomous Region 530021, People's Republic of China. 2Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong RD, Nanning, Guangxi Zhaung Autonomous Region 530021, People's Republic of China. 3Department of Pathology, Liuzhou People's Hospital, 8 Wenchang RD, Liuzhou, Guangxi Zhaung Autonomous Region 545006, People's Republic of China. 4Department of Pathophysiology, School of Pre-Clinical Medicine, Guangxi Medical University, 6 Shuangyong RD, Nanning, Guangxi Zhaung Autonomous Region 530021, People's Republic of China.

Received: 17 June 2022 Accepted: 29 October 2022

References

1. Dubey P, Gupta R, Mishra A, Kumar V, Bhadouria S, Bhatt M. LB. Evaluation of correlation between CD44, radiotherapy response, and survival rate in patients with advanced stage of head and neck squamous cell carcinoma (HNSCC). Cancer Med. 2022;11(9):1937–47.
2. Zhu GL, Yang KB, Xu C, Feng RJ, Liu WF, Ma J. Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature. Cancer Med. 2022. https://doi.org/10.1002/cam4.4791.
3. Seebauer CT,Hackenberg B, Grosse J, Rennert J, Jung EM, Ugele I, et al. Routine restaging after primary non-surgical treatment of laryngeal squamous cell carcinoma-a review. Strahlenther Onkol. 2021;197(3):167–76.
4. Sun M, Chen S, Fu M. Model establishment of prognostic-related immune genes in laryngeal squamous cell carcinoma. Medicine. 2021;100(2):e24263.
5. Cavaliere M, Bosigno A, Scarpa A, D’Urso A, Marra P, Colacurcio V, et al. Biomarkers of laryngeal squamous cell carcinoma: a review. Ann Diagn Pathol. 2021;54:151787.
6. Jen J, Wang YC. Zinc finger proteins in cancer progression. J Biomed Sci. 2016;23(1):53.
7. Ye Q, Mohamed R, Dukhailah D, Gencheva M, Hu G, Pearce MC, et al. Molecular analysis of ZNF71. KRAB in non-small-cell lung cancer. Int J Mol Sci. 2021;22(7):3752.
8. Ma Y, Ding Z, Qian Y, Wan YW, Tosun K, Shi X, et al. An integrative genomic and proteomic approach to chemosensitivity prediction. Int J Oncol. 2019;54(1):107–15.
9. Sun X, Zheng D, Guo W. Comprehensive Analysis of a zinc finger protein gene-based signature with regard to prognosis and tumor immune microenvironment in osteosarcoma. Front Genet. 2022;13:835014.
10. Wang SS, Zhai GQ, Chen G, Huang ZG, He RQ, Huang SN, et al. Decreased expression of transcription factor Homeobox A11 and its potential target genes in bladder cancer. Pathol Res Pract. 2022;238:135847.
11. Li GS, Yang LJ, Chen G, Huang SN, Fang YY, Huang WJ, et al. Laryngeal squamous cell carcinoma: clinical significance and potential mechanism of cell division cycle 45. Cancer Biother Radiopharm. 2021;37(4):300–12.
12. He RQ, Li JD, Du XF, Dang YW, Yang LJ, Huang ZG, et al. LPCAT1 overexpression promotes the progression of hepatocellular carcinoma. Cancer Cell Int. 2021;21(1):442.
13. Song L, Zhang S, Yu S, Ma F, Wang B, Zhang C, et al. Cellular heterogeneity landscape in laryngeal squamous cell carcinoma. Int J Cancer. 2020;147(10):2879–90.
14. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–20.
15. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyskoš S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–d12.
16. Zheng R, Wan C, Mei S, Qin Q, Wu Q, Sun H, et al. Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47(D1):D729–d35.
17. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

18. Ru B, Song CN, Tong Y, Zhong JJ, Zhong SS, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics (Oxford, England). 2019;35(20):4200–2.

19. anonymous. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respir Med. 2021;9(9):1030–49.

20. Wang N, Lu H, Huang M. Impact of gender on survival in patients with laryngeal squamous cell carcinoma: a propensity score matching analysis. Int J Clin Exp Pathol. 2020;13(3):573–81.

21. Li Y, Li T, Zhou D, Wei J, Li Z, Li X, et al. Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma. Cell Adhes Migr. 2021;15(1):249–60.

22. Zeisel MB, Dhawan P, Baumert TF. Tight junction proteins in gastrointestinal and liver disease. Gut. 2019;68(3):547–61.

23. Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–67.

24. Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503.

25. Huang H, Zhang H, Onuma AE, Tsung A. Neutrophil elastase and neutrophil extracellular traps in the tumor microenvironment. Adv Exp Med Biol. 2020;1263:13–23.

26. Masucci MT, Minopoli M, Del Vecchio S, Carriero MV. The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis. Front Immunol. 2020;11:1749.

27. Snuderly HF, Boone BA, Bennewitz MF. Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment. Breast Cancer Res. 2019;21(1):145.

28. Bui TM, Yalom LR, Sumagin R. Tumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance. Expert Opin Ther Targets. 2021;25(7):753–83.

29. Gardiner A, de Mingo PA, Ruffell B. Dendritic cells and their role in immunotherapy. Front Immunol. 2020;11:924.

30. Sadeghzadeh M, Bornehdeli S, Mohammadmardzakhani H, Abolghasemi M, Pourasai E, Asadi M, et al. Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci. 2020;254:117580.

31. Lee YS, Radford KJ. The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 2019;348:123–78.

32. Ando M, Itou M, Sirait T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunol Med. 2020;43(1):1–9.

33. Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):209–22.

34. Ugel S, Canè S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annu Rev Pathol. 2021;16:93–122.

35. Yan L, Song X, Yang G, Zou L, Zhu Y, Wang X. Identification and validation of immune infiltration phenotypes in laryngeal squamous cell carcinoma by integrative multi-omics analysis. Front Immunol. 2022;13:843467.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more biomedcentral.com/submissions